Cardiac Findings after COVID-19 Treatment and Completed Quarantine Process
COVID-19 Tedavisi ve Karantina Süreci Tamamlandıkta Sonraki Kardiyak Bulgular

ÖZ

Amacımız, Coronavirus disease 2019 (Covid-19) tedavisi ve karantina süreci tamamlandıkta sonra Kardiyoloji Polikliniğine başvuran hastaların geç dönemde hangi kardiyak şikayetler ile başvurduğu ve biyokimyasal parametrelerde, kardiyak biyobelirteçlerde, elektrokardiografi (EKG) ve transtorasik ekokardiografide (TTE) hangi kardiyak bulguların olduğunu tespit etmektı.

Yöntem: Bu retrospektif çalışmaya adıslık 132 hasta dahil edildi. EKG çekildi, TTE yapıldı. Tüm hastalarda başvuruda hemogram, biyokimyasal parametreler, kardiyak biyobelirteçler, yüksek duyarlılıklı kardiyak troponin T, N terminal pro B tipi natriüretik peptid ve D-dimer çalışıldı.

Bulgular: Kardiyoloji Polikliniğine başvuran hastalarda en sık görülen ko-morbidite hipertansiyon 39 (%29,50), en sık görülen kardiyak şikayeti göğüs ağrısı 48 (%36,40), en sık EKG bulgusu sinus taşıklandırısı 11 (%8,3), en sık TTE bulgusu hafif triküspti sersizliği 63 (%47,70). Çalışmada sistolik pulmoner arter hipertansiyon oranının %6,10 bu bulu ve oran normal popülsasyonu göre daha yüksek. Perikardiyal hiperkojenittenin 18 (%13,60) hastada saptanması dikkat çekiciydi. Yüksek D-dimer seviyesi 24 (%18,20) hastada, yüksek NT-proBNP seviyesi 15 (%11,40) hastada ve yüksek hs-cTn seviyesi 9 (%6,80) hastada tespit edildi.

Sonuç: Hastalar, Covid-19’u geç dönem kardiyak etkilerinin olup olmadığını araştırmak için Kardiyoloji Polikliniğinde değerlendirilmelidir.

Anahtar Kelimeler: COVID-19, elektrokardiografi, transtorasik ekokardiografı
INTRODUCTION

Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) which causes corona virus disease 2019 (COVID-19) has resulted in a world health crisis. In December 2019, COVID-19 was first described in Wuhan, China, in patients complaining of flu-like symptoms. World Health Organization declared Covid-19 as a pandemic on March 11, 2020 (1). The exact effects of COVID-19 on the cardiovascular system are not well determined but several case reports and reviews have been published. Myocarditis in COVID-19 has been recognized as the cause of death in some patients (2). COVID-19 can directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, thromboembolic events (3). Such cardiac complication sarers how both during the course of COVID-19 treatment and after the COVID-19 treatment is completed. In this study, our aim was to determinelate-term cardiac effects of COVID-19. Biochemical parameters including cardiac biomarkers, electrocardiography (ECG) and transthoracic echocardiography (TTE) were performed. Cardiac complaints of the patients who admitted to the cardiology outpatient clinic after completion of COVID-19 treatment and the quarantine process.

MATERIALS AND METHODS

This study was an observational retrospective study. Republic of Turkey Ministry of Health gave permission to do the research. This research was ethically conducted in accordance with the Declaration of Helsinki and was approved by the local institutional review board and waived the requirement for informed consent. The protocol was approved by the local ethics committee. 132 consecutive patients who were treated for COVID-19, completed quarantine process and admitted to the cardiology outpatient clinic between January 2, 2021 and February 2, 2021 were included in this retrospective study. All clinical, laboratory and outcome data were extracted from electronic medical records using a standardized data collection form and patient’s file from archive.

Cardiac complaints of the patients such as chest pain, shortness of breath, palpitation and back pain were recorded. Demographic features of the patients age, female gender, chronic diseases [diabetes mellitus (DM), hypertension (HT), hyperlipidemia (HL), chronic kidney disease (CKD), chronic hemodialysis, chronic peritoneal dialysis, chronic obstructive pulmonary disease (COPD), documented coronary artery disease, stroke history, cirrhosis] were recorded. Laboratory data on admission (glucose, creatinine, sodium, potassium, white blood cell, hemoglobin, hematocrit, glomerular filtration rates, D-dimer, high-sensitive cardiac troponin T (hs-cTn) and N terminal pro-B type natriuretic peptide (NT-proBNP) were recorded. The ECGs was performed by cardiology outpatient clinic nurses. Findings such as resting heart rate per minute, presence of normal sinus rhythm and atrial fibrillation, PR interval, QTc interval, presence of atrioventricular block, bundle branch block, sinus tachycardia and sinus bradycardia were recorded on the ECGs of the patients. TTE was conducted by the cardiologists at the cardiology outpatient clinic. Diameters was measured with M-mode. Ejection fraction was measured using Simpson method. Left ventricular ejection fraction (LVEF), right ventricular ejection fraction (RVEF), valve regurgitation, systolic pulmonary artery pressure (SPAP), pericardial effusion, pericardial hyperechogenicity were recorded.

Patients over the age of 18, diagnosed with COVID-19 with polymerase chain reaction test (PCR) positivity and admitted to the cardiology outpatient clinic after completion of COVID-19 treatment and the quarantine process, for cardiac control or due to cardiac complaints such as chest pain, shortness of breath, palpitation and back pain were included in the study.

Patients under 18 years of age, hospitalized patients, patients with chronic heart failure (EF lower than 50%), acute renal failure, chronic renal failure [glomerular filtration rate (GFR) below 60 ml/ min/1.73 m²], acute liver failure, cirrhosis, history of tuberculosis, history of autoimmune conditions, hyperthyroidism, hypothyroidism and patients on hemodialysis or peritoneal dialysis were excluded from the study.
SPSS software for Windows (release 15.0.0, SPSS, Chicago, IL) was used for statistical analysis. The Kolmogorov-Smirnov test was used to determine the normality of the variables. Continuous variables were reported as mean-standard deviation or median (IQR). Categorical variables were reported as the number (percentage) of participants.

RESULTS

In the study we included patients over the age of 18, diagnosed as COVID-19 with PCR positivity and admitted to the cardiology out-patient clinic after completion of COVID-19 treatment and the quarantine process, for cardiac control or due to cardiac complaints.

The admission of the patients to the cardiology out-patient clinic was median 30 (14-150) days after the completion of the quarantine process.

87 (66%) of the patients were women and 45 (34%) of the patients were men. The mean age was 43.76±13.45 years. The accompanying comorbidities of the all the patients were as follows: DM 17 (12.9%), HT 39 (29.5%), HL 20 (15.2%), CAD 16 (12.1%), COPD 6 (4.5%), stroke history 1 (0.8%), metallic mitral valve prosthesis 1 (0.8%). The basic clinical characteristics of the patients, including age, gender, comorbidities are listed in Table 1.

| Table 1: The Basic Clinical Characteristics of the Patients |
|-----------------------------------------------------------|
| Age (mean±SD), years | 43.76±13.45 |
| Sex | n | % |
| Male | 45 | 34 |
| Female | 87 | 66 |
| Hypertension | 39 | 29.5 |
| Diabetes mellitus | 17 | 12.9 |
| Hyperlipidemia | 20 | 15.2 |
| Coronary artery disease | 16 | 12.1 |
| Chronic obstructive pulmonary disease | 6 | 4.5 |
| Stroke | 1 | 0.8 |
| Mitral valve prosthesis | 1 | 0.8 |
| n: number SD: standard deviation |

Chest pain, shortness of breath, palpitation and back pain were present in 48 (36.40%), 21 (15.90%), 27 (20.50%) and 18 (13.63%) patients, respectively (Table 2).

| Table 2: Complaints of the Patients Presenting to the Cardiology Outpatient Clinic |
|-----------------------------------------------|
| n | % |
| Back pain | 18 | 13.63 |
| Angina | 48 | 36.4 |
| Dyspnea | 21 | 15.9 |
| Palpitation | 27 | 20.5 |
| n: number |

Median resting heart rate was 79.00 (66.10-99.00) beat per minute, atrial fibrillation was present in 2 (1.5%), sinus tachycardia in 11 (8.3%), sinus bradycardia in 3 (2.3%), right bundle branch block in 6 (4.5%), left bundle branch block in 1 (0.8%), atrial extrasystole in 7 (5.3%), ventricular extrasystole in 5 (3.8%) patients. Mean PR interval, median QTc interval and median QRS duration were 148.99±19.63 millisecond (ms), 399.00 (377.90-427.10) ms, and 85.50 (75.00-102.00) ms, respectively. Short PR interval was present in 7 (5.3%) patients. Long PR interval was detected in 2 (1.5%) patients. Long QTc was found in 5 (3.8%) patients. Left ventricular hypertrophy was present in 5 (3.8%) patients. ECG findings of the patients are shown in Table 3.

Median LVEF was 60% (60-65), LV hypertrophy was present in 14 (10.60%), LV diastolic dysfunction in 15 (11.40%), mild mitral regurgitation in 32 (24.20%), moderate mitral regurgitation in 3 (2.30%), mild tricuspid regurgitation in 63 (47.70%) patients. Median SPAP was 25.00 mmHg (20.00-35.00). Pericardial hyperechogenicity was present in 18 (13.60%), mild aortic regurgitation in 8 (6.10%), systolic pulmonary arterial hypertension (sPAH) in 8 (6.10%) patients. TTE findings of the patients are shown in Table 4.

Median glucose level was 98 (84.00-140.30) mg/dL and median creatinine level was 0.70 (0.60-1.00) mg/dL.
Table 3: Electrocardiography Findings of the Patients

|                                  | bpm | ms  | median | IQR   | mean ± SD | n  | %   |
|----------------------------------|-----|-----|--------|-------|-----------|----|-----|
| Heart rate                       | 79.00 | 66.1 | 96.0   |       |           |    |     |
| Tachycardia                      |     |     |        |       |           | 11 | 8.3 |
| Bradycardia                      |     |     |        |       |           | 3  | 2.3 |
| Right bundle branch block        |     |     |        |       |           | 6  | 4.5 |
| Left bundle branch block         |     |     |        |       |           | 1  | 0.8 |
| Atrial extrasystole              |     |     |        |       |           | 7  | 5.3 |
| Ventricular extrasystole         |     |     |        |       |           | 5  | 3.8 |
| PR interval                      |     |     |        |       |           | 148.99 ± 19.630 |  |
| QTc interval                     |     |     |        |       |           | 399.0 | 377.9 | 47.1 |
| Left ventricular hypertrophy     |     |     |        |       |           | 5  | 3.8 |
| QRS duration                     |     |     |        |       |           | 85.5 | 75.0 | 102.0 |
| Short PR interval                |     |     |        |       |           | 7  | 5.3 |

bpm: beats per minute, IQR: Inter Quantile, n: number, SD: standard deviation, ms: millisecond

Table 4: Transthoracic Echocardiography Findings of the Patients

|                                    | mmHg | median | IQR | n  | %   |
|------------------------------------|------|--------|-----|----|-----|
| Left ventricular hypertrophy       |      |        |     | 14 | 10.6|
| Ejection fraction                  |      | 60     | 65  | 60.0 | |
| Left ventricular diastolic dysfunction |      |        |     | 15 | 11.4|
| Mild mitral regurgitation          |      | 32     |     | 24.2 | |
| Moderate mitral regurgitation      |      | 3      |     | 2.3 | |
| Tricuspid regurgitation            |      | 63     |     | 47.7 | |
| Systolic pulmonary arterial pressure |      | 25.0   | 20  | 35 | |
| Pericardial effusion               |      | 2      |     | 1.5 | |

IQR: Inter Quantile Range, n: number

Median urea, mean GFR, median sodium and median potassium levels were 26.00 (15.00-39.00) mg/dl, 103.48±16.70, 139.00 (136.00-142.00) mmol/L and 4.20 (3.80-4.80) mmol/L, respectively. Median alanine amino transferase level was 17.00 (8.00-36.00) U/L and median aspartate amino transferase level was 18.00 (13.20-28.60) U/L. Median CRP level was calculated as 2.50 (0.45-13.10) mg/L. Median thyroid stimulating hormone was 1.50 (0.90-3.08) IU/mL. Median hemoglobin level, mean hematocrit, mean white blood count (WBC) and median thrombocyte count were 13.10 (11.04-15.68) mg/dL, 40.04±4.42%, 7.40±2.43 10^3/L and 254.00 (188.40-348.80) 10^3/L, respectively. Median hs-cTnI level was 3.30 (3.00-12.00) ng/mL and median NT-proBNP level was 53.50 (13.32-203.90) pg/mL. Median D-dimer level was calculated as 0.20 (0.20-0.84) μg/ml. Anemia was present in 23 (17.40%) patients. High CRP was found in 28 (21.20%), high WBC in 19 (14.40), low thrombocyte in 1 (0.8%), high thrombocyte in 5 (3.8%), high hs-cTnI in 9 (6.8%), high D-dimer in 24 (18.20%) μg/ml and high NT-proBNP in 15 (11.40%) patients. Laboratory findings of patients on admission are shown in Table 5.
| Table 5: Laboratory Findings of Patients on Admission | n   | %          |
|---------------------------------------------------|-----|------------|
| Glucose (mg/dl) median (IQR)                       | 98.00 (84.00-140.30) | 74-106mg/dl |
| Urea (mg/dl) median (IQR)                          | 26.00 (15.00-39.00)  | 10-50mg/dL  |
| Creatinine (mg/dl) median (IQR)                    | 0.70 (0.60-1.00)      | 0.5-0.9mg/dL|
| Sodium (mmol/L) median (IQR)                       | 139.00 (136.00-142.00)| 135-148mmol/L|
| Glucose (mg/dl) median (IQR)                       | 4.20 (3.80-4.80)      | 3.4-4.5mmol/L|
| Glomerular filtration rate mean ± SD              | 103.48 ± 16.70        | 52-110mL/min |
| Alanine aminotransferase (U/L) median (IQR)       | 17.00 (8.00-36.00)    | 0-33U/L     |
| Aspartate aminotransferase (U/L) median (IQR)     | 18.00 (13.20-28.60)   | 0-32U/L     |
| CRP (mg/L) median (IQR)                            | 2.50 (0.45-13.10)     | 0-5mg/L     |
| Thyroid stimulating hormone (µIU/mL) median (IQR) | 1.50 (0.90-3.08)      | 0.270-4.20µIU/mL |
| White blood count (10^3/µL) mean ± SD             | 7.40 ± 2.43           | 3.98-10.04 10^3/µL |
| Hemoglobin (g/dl) median (IQR)                     | 13.10 (11.04-15.68)   | 11.7-16.0 g/ dL |
| Hematocrit (%) mean ± SD                          | 40.04 ± 4.42          | 35-47%      |
| Thrombocyte (10^3/µL) median (IQR)                | 254.00 (188.40-348.80)| 150-388 10^3/µL |
| High sensitive cardiac troponin T (ng/L) median (IQR) | 3.30 (3.00-12.00)     | 0-14ng/L    |
| D-Dimer (µg/mL) median (IQR)                       | 0.20 (0.20-0.84)      | 0-0.5µg/ml  |
| NT-proBNP (pg/mL) median (IQR)                     | 53.50 (13.32-203.90)  | 0-125pg/mL  |
| High CRP                                           | 2 8                        | 21.2          |
| High white blood count                             | 1 9                        | 14.4          |
| Anemia                                             | 2 3                        | 17.4          |
| Low thrombocyte                                    | 1 0                        | 0.80          |
| High thrombocyte                                   | 5 0                        | 0.80          |
| High sensitive cardiac Troponin T                 | 9 6.80                     |               |
| High D-Dimer                                       | 2 18.2                     |               |
| High NT-ProBNP                                     | 1 11.4                     |               |

bpm: beats per minute, IQR: Inter Quantile Range, n: number, SD: standard deviation, ms: millisecond, mg/dl: milligram/deciliter, mmol/L: millimole/liter, µIU/mL: micro international unit/milliliter, µg/mL: microgram/milliliter, µL: microliter, pg/mL: picogram/milliliter, NT-proBNP: N terminal Pro B type natriuretic peptid, CRP: C reactive protein, ng/L: nanogram/liter, U/L: unit/liter
DISCUSSION

In the study we included patients over the age of 18, diagnosed as COVID-19 with PCR positivity and admitted to the cardiology out-patient clinic after completion of COVID-19 treatment and the quarantine process, for cardiac control or due to cardiac complaints. The majority of the patients were women; three of them were in postpartum period, one of them was a 35-week pregnant woman. 21 year-old 35-week pregnant patient was hospitalized with symptoms of chest pain and palpitation. She had high WBC and D-dimer levels. A total of six patients were diagnosed with a cute pericarditis. Two of them were hospitalized because they had acute pericarditis with pericardial effusion. We have defined this clinical situation as a delayed complication of COVID-19 infection. The other four patients were treated at out-patient clinic.

In this study, the most common co-morbidity was HT, seen in 39 (29.5%) patients. As mentioned in previous literature, hypertension is a risk factor for COVID-19. This finding was supported by our study. The most common complaint of the patients presenting to the cardiology out-patient clinic was chest pain, seen in 48 (36.40%) patients. The characteristic of this chest pain was pleuritic. It did not meet the typical angina criteria. Acute coronary syndrome was not detected in any patient. A 45-year-old woman had a positive cardiovascular stres test and invasive coronary angiography was performed which revealed non-critical coronary stenosis.

When the echocardiographic findings were analyzed, the most common finding was mild tricuspid regurgitation. Mild tricuspid regurgitation was mostly considered physiological. We used Bernoulli equation to measure the SPAP. We detected sPAH in 8 (6.10%) patients. Moreira EM et al. found the prevalence of echocardiographic pulmonary hypertension to be 2.6% (95% CI: 2.0; 3.2) in the general population (4). In our study, we think that such a high rate of sPAH, compared to the normal population, was a result of secondary pulmonary hypertension due to the damage of the lung. In addition to this finding, pericardial hyperechogenicity was detected in 18 (13.60%) patients. Pericardial hyperechogenicity was observed especially, adjacent to the left ventricular lateral wall in four-chamber view and left ventricular posterior wall in parasternal long axis view. As with other viral infections, it has been postulated that COVID-19 may trigger cascades of inflammatory path ways which can potentially result in multi-organ injury including heart, lung, and the serosal surface encompassing them. When COVID-19 elicits this inflammatory response, it is reasonable that this may lead to pericarditis and pericardial effusion similar to other viral infections (5). SARS-CoV-2 which belongs to coronavirinae sub family, is a single-strand RNA coronavirus, which enters human cells mainly by binding the angiotensin-converting enzyme 2 (ACE2) receptor (6). ACE2 is mainly located at human oral pharynx, upperairway, heart, liver, kidney, intestine, neuron, and testis. (7). Generally, COVID-19 predominantly presents with respiratory symptoms and pulmonary injury, but as cases have multiplied, there has been increasing awareness of its cardiovascular involvement (8). Some cases of pericardial involvement during and after symptomatic COVID-19 infection have been reported. In a case study, the presence of COVID-19 in the pericardial fluid was detected using PCR on pericardial fluid (9). Until polymerase chain reaction testing for COVID-19 on pericardial fluid becomes more available, work-up to rule out other causes should be completed before considering COVID-19 as the cause of the disease (10). In this study other echocardiographic findings were not different from the normal population.

When the laboratory findings were analyzed, elevated D-dimer levels were detected in 24 (18.20%) patients. Severe COVID-19 can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism (11). It has been reported that COVID-19 was associated with hemostatic abnormalities and markedly elevated D-dimer levels were observed (12-13). It is unknown how long D-dimer remains high during and after the course of Covid-19 infection. We continued subcutaneous enoxaparin treatment on these patients.
We detected elevated hs-cTn levels in 9 (6.8%) patients. The elevation of hs-cTn in the absence of acute coronary syndrome is likely to be multifactorial, including myocardial ischemia, increased wall tension and ventricular arrhythmias, direct myocardial trauma, excess catecholamines, and possibly impaired renal clearance (14). Since patients with acute kidney disease and chronic kidney disease were not included in our study, elevated hs-cTn cannot be attributed to these diseases. Therefore, elevated hs-cTn levels were attributed to acute pericarditis and sPAH related right ventricular increased wall tension.

We detected elevated NT-proBNP levels in 15 (11.40%) patients. NT-proBNP levels increase in heart failure (15), chronic kidney disease (16) and cirrhosis (17). Since patients with acute kidney disease, chronic kidney disease, cirrhosis were not included in our study and there was no patient with heart failure; elevated hs-cTn levels can not be attributed to these diseases. Therefore, elevated NT-proBNP levels were attributed to mitral regurgitation, tricuspid regurgitation, and sPAH related right ventricular increased wall tension.

The most common ECG finding was sinus tachycardia, detected in 11 (8.3%) patients. In our study other ECG findings were not different from the normal population. COVID-19 related cardiac arrhythmias such as; high-grade AV block, new onset atrial fibrillation, polymorphic ventricular tachycardia, and ventricular premature contraction causing a long-short sequence, and cardiac arrest with pulseless electrical activity detected in a recent case series. In our study other ECG findings were not different from the normal population (18).

Until now, a study examining the late cardiac effects seen in COVID-19 patients who have completed COVID-19 treatment and quarantine process has not been found in the literature. This study has several limitations. Firstly, our study was a single-center and retrospective study. Secondly, the number of patients participating in the study was small. In order to reveal the late cardiac effects of COVID-19, studies are needed with larger patient groups.

CONCLUSION
We think that sPAH, pericardial hyperechogenicity, myocarditis and sinus tachycardia detected in study patients are associated with recent COVID-19 infection. If sPAH is detected in these patients, lung damage and pulmonary embolism should be sought. Chest computed tomography (CT) scan and contrast-enhanced CT scan should be performed and D-dimer level should be measured. It was also remarkable that pericardial hyperechogenicity was detected in these patients. COVID-19 pathological cardiacs equalae include pericard it is with or without pericardial effusion. The patients with pericarditis should be treated with colchicine and methylprednisolone. Myocarditis should be investigated in patients with high hs-cTn and lower LVEF. Cardiac magnetic resonance imaging should be performed to investigate whether there is myocardial fibrosis in late gadolinium enhancement sequences. ECG and Rhythm holtermonitorization may be performed to detect cardiac arrhythmias in patients with palpitations. Therefore, these patients should be evaluated in the cardiology out-patient clinic to investigate whether they have late-term cardiac effects due to COVID-19 infection.

Conflict of Interest
The authors declares that they have no conflict interests regarding content of this article.

Funding
No financial support was used by authors during this study.

Ethics Committee Approval
Republic of Turkey Ministry of Health gave permission to do the research. This research was ethically conducted in accordance with the Declaration of Helsinki (28th January 2021 and no 2021/2).

Informed Consent
Since this study was a retrospective study, informed consent was not obtained from the patients.
REFERENCES

1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Reports [Internet].
2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. Epub 2020 Mar 3. Erratum in: Intensive Care Med. 2020 Apr 6. PMID: 32125452; PMCID: PMC7080116. https://doi.org/10.1007/s00134-020-05991-x
3. Su YB, Kuo MJ, Lin TY, Chien CS, Yang YP, Chou SJ, Lee HB. Cardiovascular manifestation and treatment in COVID-19. J Chin Med Assoc. 2020 Aug;83(8):704-709. PMID: 32433342; PMCID: PMC7493780. https://doi.org/10.1097/JCMA.0000000000000352
4. Moreira EM, Gall H, Leening MJ, et al. Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. PLoS One. 2015;10(6):e0130072. Published 2015 Jun 23. https://doi.org/10.1371/journal.pone.0130072
5. Vakamudi S, Ho N, Cremer PC. Pericardial Effusions: Causes, Diagnosis, and Management. Prog Cardiovasc Dis. 2017 Jan-Feb;59(4):380-388. Epub 2017 Jan 4. PMID: 28062268. https://doi.org/10.1016/j.pcad.2016.12.009
6. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281-292.e6. Epub 2020 Mar 9. Erratum in: Cell. 2020 Dec 10;183(6):1735. PMID: 32155444; PMCID: PMC7102599. https://doi.org/10.1016/j.cell.2020.02.058
7. Landi A, Iannucci V, Nuffel AV, Meuwissen P, Verhasselt B. One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef. Curr HIV Res. 2011 Oct;9(7):496-504. PMID: 22103833; PMCID: PMC3290772. https://doi.org/10.2174/157016211798842116
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:15; 395(10223): 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
9. Farina A, Uccello G, Sprefaico M, Bassanelli G, Savonitto S. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J Intern Med. 2020;76:100-101. https://doi.org/10.1016/j.ejim.2020.04.045
10. Asif T, Kassab K, Iskander F, Alyousef T. Acute Pericarditis and Cardiac Tamponade in a Patient with COVID-19: A Therapeutic Challenge. Eur J Case Rep Intern Med. 2020;7(6):001701. Published 2020 May 6. https://doi.org/10.12890/2020_001701
11. Zhang L, Long Y, Xiao H, Yang J, Toulon P, Zhang Z. Use of D-dimer in oral anticoagulation therapy. Int J Lab Hematol. 2018 Oct;40(5):503-507. Epub 2018 May 27. PMID: 29806239. https://doi.org/10.1111/ijlh.12864
12. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. Epub 2020 Mar 13. PMID: 32073213; PMCID: PMC7166509. https://doi.org/10.1111/jth.14768
13. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020 May 14;41(19):1858. PMID: 32227120; PMCID: PMC7184406. https://doi.org/10.1093/eurheartj/ehaa254
14. Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol. 2013 Nov;10(11):623-34. Epub 2013 Aug 27. PMID: 23979214. https://doi.org/10.1038/nrcardio.2013.129
15. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010 Jun 1;6:411-8.PMID: 20539843; PMCID: PMC2882893. https://doi.org/10.2147/vhrm.s5789
16. Niizuma S, Iwanaga Y, Yahata T, Goto Y, Kita T, Miyazaki S, et al. Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients, Nephrology Dialysis Transplantation, Volume 24, Issue 2, February 2009, Pages 597–603, https://doi.org/10.1093/ndt/gfn491
17. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003 Oct;52(10):1511-7. PMID: 12970147; PMCID: PMC1773816. https://doi.org/10.1136/gut.52.10.1511

18. Kochav SM, Coromilas E, Nalbandian A, Ranard LS, Gupta A, Chung MA, et al. Cardiac Arrhythmias in COVID-19 Infection. Arrhythmia and Electrophysiology. 2020;13:e008719 https://doi.org/10.1161/CIRCEP.120.008719